@BactLAB(TM), Bacterial Colony-counting Service, Now Available Globally

Food and Healthcare Press Releases Monday August 5, 2019 12:00
TOKYO--5 Aug--Kyodo JBN- AsiaNet/InfoQuest

Nissui Pharmaceutical Co., Ltd., based in Tokyo, is pleased to announce that @BactLAB(TM), an application that uses Amazon Web Service (AWS) Cloud and artificial intelligence (AI) technologies to enable quick and easy counting of bacterial colonies, is now available to overseas users of CompactDry(TM). The launch of this application is part of the company's strategy of active investment in areas of new growth for the purpose of contributing to the development of overseas markets and quality control processes in relation to food hygiene.

(Logo1: https://kyodonewsprwire.jp/prwfile/release/M105074/201907319276/_prw_PI1fl_1Mft9204.jpg)
(Logo2: https://kyodonewsprwire.jp/img/201907319276-O2-u1982f9w)

Since August 2018, a limited number of Nissui Pharmaceutical's overseas customers have been testing and using @BactLAB(TM), a colony counter application developed exclusively for CompactDry(TM), an easy-to-use medium for measuring bacteria count and also the company's most important product for overseas customers. During this phase, it made several improvements to the application, such as faster counting of colonies, collecting and utilizing AI learning data, new convenience features and additional functions, all of which are now included in the released service.

@BactLAB(TM) official website:
https://www.nissui-pharm.co.jp/english/products/global/bactlab/
Application available at: Google Play / Apple Store / Amazon Appstore / Online Service
(Images1: https://kyodonewsprwire.jp/img/201907319276-O3-TipIpw4F)
@BactLAB(TM) Service Overview
  • Auto count with global cloud access, available on multiple devices (PC / Android / iPhone)
  • Cloud storage function of counted data
  • Exportable reports (in .csv file or .jpg file format)
  • Chat Bot support on the official website
* This service is an application designed exclusively for CompactDry(TM) customers.
* A Wi-Fi environment is recommended when using the smartphone app.
* Depending on the target image, there may be a counting error of up to 8%.
* A colony count result of "0" does not indicate a negative result.
* Nissui Pharmaceutical takes no responsibility for the analysis results provided by this service.
(Images2: https://kyodonewsprwire.jp/prwfile/release/M105074/201907319276/_prw_PI4fl_D1wtD48F.png)
* Google, Google Play, Android and other such marks are trademarks of Google Inc.
* Apple and the Apple logo are trademarks of Apple Inc. registered in the USA and other countries. App Store, AppleCare and iCloud are service marks of Apple Inc. (TM) and (R) Apple Inc. All rights reserved.
* Amazon and Amazon Web Service are trademarks or registered trademarks of Amazon.com, Inc. or its affiliates.
SOURCE: Nissui Pharmaceutical Co., Ltd.
AsiaNet 79935

Latest Press Release

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

United Nations Political Declaration on Universal Health Coverage Finally has Some Teeth

FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC). The declaration will be officially adopted by world leaders at the UN High-Level...

Ozempic(R) Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza(R) and Canagliflozin in People With Type 2 Diabetes

Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin...

Related Topics